GlassScriptPhysician profile
Spencer Silverbach
NPI 1245287846
$2,977.05
in general payments reported to CMS, 2019-2025
25 companies · $24.47 in 2025
The $24.47 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $189 · 2021: $502 · 2022: $947 · 2023: $197 · 2024: $21.07 · 2025: $24.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $770.83 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $627.16 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $450.05 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $236.52 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.43 | 2019-2022 | |
| Glaxosmithkline, LLC. | $107.80 | 2019-2023 | Bexsero, Shingrix |
| Sunovion Pharmaceuticals INC. | $106.84 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.50 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.99 | 2022 | |
| Astellas Pharma US INC | $44.40 | 2021 | |
| Hologic Sales and Service, LLC | $42.65 | 2023-2024 | Aptima |
| Avanir Pharmaceuticals, INC. | $38.34 | 2019 | |
| Amgen INC. | $33.72 | 2019 | |
| Amarin Pharma, INC. | $27.33 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $24.52 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $24.21 | 2021 | |
| Sanofi Pasteur INC. | $21.83 | 2019 | |
| Allergan, INC. | $17.83 | 2020 | |
| Livanova USA, INC. | $17.69 | 2021 | |
| Eisai INC. | $17.30 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2020 | |
| Lilly USA, LLC | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Silverbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.